Condition: Transfusion-dependent Beta-Thalassemia · Sponsor: Kanglin Biotechnology (Hangzhou) Co., Ltd.
This is a non-randomized, open label, single-dose study in up to 41 participants with β-thalassemia major. The goal of this clinical trial is to evaluate the safety and efficacy of KL003 cell injection in subjects with β-thalassemia major.
This description comes directly from the study's public registry record.
jingfeng Yan · +86 18852138866 · yanjingfeng@kanglinbio.com
Always discuss trial participation with your own doctor first.
| Ruijin Hospital, Shanghai Jiaotong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
| Institute of Hematology & Blood Diseases Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06280378